### Implantable Cardioverter Defibrillator (ICD) Devices

## Fortify<sup>™</sup> DR

#### Dual-Chamber Implantable Cardioverter Defibrillator (ICD)

### **Product Highlights**

- ShockGuard<sup>™</sup> technology with DecisionTx<sup>™</sup> programming, designed to reduce inappropriate therapy and minimise the need for programming adjustments at implant
- Unique 40 J delivered energy safety shock option can provide a greater DFT safety margin
- The DF4 connector is designed to simplify implants by streamlining defibrillation connections into a single terminal pin and reducing the number of set screws
- QHR<sup>™</sup>\* chemistry battery provides greater capacity for enhanced longevity and stable charge times
- Antitachycardia pacing (ATP) while charging and prior to charging in the VF zone further extends the programming options for terminating tachyarrhythmias without a high-voltage shock
- The low frequency attenuation filter is designed to enhance sensing performance and may reduce the possibility of oversensing T waves
- DeFT Response<sup>™</sup> technology offers the most noninvasive options for managing high DFTs
- Vibratory patient notifier enables patients with hearing problems to be alerted to a low battery, lead-related complications and more
- The Sense*Ability*<sup>™</sup> feature provides the flexibility to fine-tune programming around T-wave oversensing without decreasing sensitivity
- Ventricular Intrinsic Preference (VIP<sup>™</sup>) algorithm automatically searches for intrinsic conduction

## Ordering Information

Contents: Cardiac pulse generator

Model Number	Dimensions (H x W x T, mm)	Weight (g)	Volume (cc)	Connector Defibrillation	Connector Sense/Pace
CD2233-40	74 x 40 x 14	76	35	DF1	IS-1
CD2233-40Q	71 x 40 x 14	75	35	DF4	IS-1; DF4

Indications: The devices are intended to provide ventricular antitachycardia pacing and ventricular defibrillation for automated treatment of life-threatening ventricular arrhythmias.

**Contraindications:** Contraindications for use of the pulse generator system include ventricular tachyarrhythmias resulting from transient or correctable factors such as drug toxicity, electrolyte imbalance, or acute myocardial infarction.

#### Adverse Events:

Implantation of the pulse generator system, like that of any other device, involves risks, some possibly life-threatening. These include but are not limited to the following: acute hemorrhage/bleeding, air emboli, arrhythmia acceleration, cardiac or venous perforation, cardiagenic shock, cyst formation, erosion, exacerbation of heart failure, extrusion, fibrotic tissue growth, fluid accumulation, hematoma formation, histotoxic reactions, infection, keloid formation, myocardial irritability, nerve damage, pneumothorax, thromboemboli, venous occlusion. Other possible adverse effects include mortality due to: component failure, device-programmer communication failure, lead abrasion, lead dislodgment or poor lead placement, lead fracture, inability to defibrillate, inhibited therapy for a ventricular tachycardia, interruption of function due to electrical or magnetic interference, shunting of energy from defibrillation paddles, system failure due to ionising radiation. Other possible adverse effects include mortality due to inappropriate delivery of therapy caused by: multiple counting of cardiac events including T waves, P waves, or supplemental pacemaker stimuli. Among the psychological effects of device implantation are imagined pulsing, dependency, fear of inappropriate pulsing, and fear of losing pulse capability.

Refer to the User's Manual for detailed indications, contraindications, warnings, precautions and potential adverse events.



Brief Summary: Prior to using these devices, please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precations, potential adverse events and directions for use. Devices depicted may not be available in all countries. Check with your St. Jude Medical representative for product availability in your country. Unless otherwise noted, ™ indicates that the name is a trademark of, or licensed to, St. Jude Medical or one of its subsidiaries. ST. JUDE MEDICAL, the nine-squares symbol and MORE CONTROL. LESS RISK. are registered and unregistered trademarks and service marks of St. Jude Medical, Inc. and its related companies. ©2011 St. Jude Medical, Inc. All rights reserved.



Merlin@home™ Transmitter Compatible



# Fortify<sup>™</sup> DR

Dual-Chamber Implantable Cardioverter Defibrillator (ICD)

## **Product Specifications**

PHYSICAL SPECIFICATIONS			Post Therapy Pacing (Independent	ly programmable from Bradycardia and ATP)	
<b>Models</b> Telemetry Delivered/Stored Energy (J)	<b>CD2233-40</b> RF 40/45	<b>CD2233-40Q</b> RF 40/45	Post-Shock Pacing Mode Post-Shock Base Rate (min <sup>-1</sup> ) Post-Shock Pacing Duration (min)	Off; AAI; VVI; DDI; DDD 30-100 in increments of 5 Off; 0,5; 1, 2,5; 5; 7,5; or 10	
Volume (cc) Weight (g)	35 76	35 75	Device Testing/Induction Methods		
Size (mm) Defibrillation Lead Connections Sense/Pace Lead Connections High-Voltage Can	74 x 40 x 14 DF1 IS-1 Electrically active titanium can	71 x 40 x 14 DF4 DF4 Electrically active titanium can	DC Fibber™ Pulse Duration (sec) Burst Fibber Cycle Length (ms) Noninvasive Programmed Stimulation (NIPS)	0,5-5,0 20-100 2-25 stimuli with up to three extrastimuli	
PARAMETER	SETTINGS		Patient Notifiers		
AF Management AF Suppression <sup>™</sup> Pacing No. of Overdrive Pacing Cycles Maximum AF Suppression Rate Sensing/Detection	On; Off 15-40 in steps of 5 80-150 min <sup>-1</sup>		Programmable Notifiers (On; Off) Device Parameter Reset Entry into Backup VVI Mode Vibration Duration (sec)	Device at ERI; Charge Time Limit Reached; Possible HV Circuit Damage; Atrial Lead Impedance Out of Range; Ventricular Lead Impedance Out of Range; High-Voltage Lead Impedance Out of Range, H7AF Burden; V Rate During AT/AF; % V pacing; CorVue Congestion Trigger On On 2; 4; 6; 8; 10; 12; 14; 16	
Sense <i>Ability</i> <sup>—</sup> Technology Low Frequency Attenuation Threshold Start	reshold Start (Post-Sensed; Atrial) 50; 62,5; 75; 100%; (Post-Paced; Atrial) 0,2-3,0 mV; (Post-Sensed; Ventricular) 50; 62,5; 75; 100%; (Post-Sensed; Ventricular) 4,04; 0,2-3,0 mV (Post-Sense/Post-Pace; Atrial/Ventricular) 0-220 1tricular Sense Refractory (ms) 125; 157 tection Zones VT-1; VT-2; VF T Discriminators AV Rate Branch; Sudden Onset; Interval Stability; Morphology Discrimination (MD) with Manual or Automatic Template Update		Number of Vibrations per Notification Number of Notifications Time Between Notifications (hours)		
			<b>Electrograms and Diagnostics</b>		
Decay Delay Ventricular Sense Refractory (ms) Detection Zones SVT Discriminators			Stored Electrograms	Up to 45 minutes including up to one minute programmable pre-trigg data per VT/VF diagnosis/detection electrograms; triggers include diagnosis; therapy; atrial episode; PMT termination; PC shock deliver noise reversion; magnet reversion; and morphology template verificat	
Reconfirmation			Therapy Summary Episodes Summary	Diagram of therapies delivered Directory listing of up to 60 episodes with access to more details includin stored electrograms	
Antitachycardia Pacing Therapy			Lifetime Diagnostics	History of bradycardia events and device-initiated charging	
ATP Configurations ATP in VF Zone ATP Upper Rate Cutoff Burst Cycle Length Min. Burst Cycle Length (ms) Number of Bursts Number of Stimuli Add Stimuli per Burst ATP Pulse Amplitude (V) ATP Pulse Width (ms)	Ramp; Burst; Scan; 1 or 2 schemes per VT zone ATP While Charging; ATP Prior to Charging; Off 150 - 300 bpm Adaptive; Readaptive or Fixed 150 - 400 in increments of 5 1-15 2-20 On; Off 7,5 Independent from Bradycardia and Post-Therapy Pacing 1,0 or 1,5 Independently programmable from Bradycardia		AT/AF Burden Trend Ventricular HV Lead Impedance Trend Histograms PMT Data Real-Time Measurements (RTM) CorVue™ Congestion Monitoring	Trend data and counts Multi-Vector Trend Data Event Histogram; AV Interval Histogram; Mode Switch Duration Histogram; Peak Filtered Rate Histogram; Atrial Heart Rate Histogram; Ventricular Heart Rate Histogram; AT/AF Burden; Exercise and Activity Trending; V Rates during AMS Information regarding PMT detections Pacing lead impedances; high-voltage lead impedances; unloaded battery voltage; and signal amplitudes On; Off	
	and Post-Therapy Pacing		CorVue Congestion Trigger	8-18 days	
High-Voltage Therapy					
High-Voltage Output Mode Waveform RV Polarity Electrode Configuration <b>Bradycardia Pacing</b>	Fixed Pulse Width; Fixed Tilt Biphasic; Monophasic Cathode (-); Anode (+) RV to Can; RV to SVC/Can		*QHR is a trademark of Greatbatch, L	TD.	
Permanent Modes Temporary Modes Rate-Adaptive Sensor Programmable Rate and Delay Parameters	Maximum Sensor Rate (min <sup>-1</sup> ); Pac Rate Responsive AV Delay; Pulse A	V00; A00			
QuickOpt <sup>™</sup> Timing Cycle Optimisation Auto Mode Switch (AMS) Atrial Tachycardia Detection Rate (min <sup>-1</sup> )					
AMS Base Rate (min <sup>-1</sup> ) Auto PMT Detection/Termination Rate Responsive PVARP/VREF Ventricular Intrinsic Preference (VIP™) Ventricular AutoCapture <sup>™</sup>	40; 45;135 A Pace on PMT; Off; Passive Off; Low; Medium; High Off; 50-200 (50-150 in increments On; Off	of 25; 160-200 in increments of 10)			
Pacing System ACap™ Confirm	On; Monitor; Off				

#### Customer Support: 46-8-474-4756

Brief Summary: Prior to using these devices, please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions, potential adverse events and directions for use. Devices depicted may not be available in all countries. Check with your St. Jude Medical representative for product availability in your country. Unless otherwise noted, <sup>TM</sup> indicates that the name is a trademark of, or licensed to, St. Jude Medical or one of its subsidiaries. ST. JUDE MEDICAL, the nine-squares symbol and MORE CONTROL. LESS RISK. are registered and unregistered trademarks and service marks of St. Jude Medical, Inc. and its related companies. ©2011 St. Jude Medical, Inc. All rights reserved.



Item GMCRM779EN